What Ceribell does

Ceribell, Inc. (NASDAQ: CBLL) is a medical technology company founded in 2014 and headquartered in Sunnyvale, California, that has built a point-of-care EEG platform for rapid bedside brain monitoring in non-specialist settings such as intensive care units, emergency departments, and neonatal/pediatric ICUs. The platform pairs a portable recorder with a disposable single-use headband and a cloud-based portal, allowing any trained clinician to initiate EEG monitoring within minutes without requiring a dedicated EEG technologist. Layered on the hardware is the proprietary Clarity AI algorithm — an FDA-cleared machine-learning model that interprets EEG waveforms in near real time, computes a rolling seizure-burden estimate, and issues color-coded bedside alerts. The company also offers the Brain Stethoscope sonification feature, a FedRAMP High-authorized EEG Portal for remote neurologist review, and a neonatal headband variant for preterm and newborn patients.

Ceribell operates a hybrid revenue model combining one-time hardware placement (recorders deployed at hospitals) with per-patient recurring consumable revenue from disposable headbands and a software/AI subscription for Clarity and the EEG Portal. Pricing is quote-based under multi-year contracts, and hospitals can leverage CMS New Technology Add-on Payments (NTAP) of up to $913.90 per eligible patient as well as existing CPT codes to support procedure-level reimbursement. The company is installed at 600+ U.S. hospitals (~11% of U.S. hospitals) and has expanded its sales force from approximately 35 to 55 territories; a recent FedRAMP High authorization opens the 170-hospital U.S. Veterans Affairs system. Following a $53 million Series C in 2021, Ceribell completed its NASDAQ IPO in October 2024, raising approximately $180 million at a $578 million valuation.

FY2025 revenue reached $89.1 million (36% YoY growth) on approximately 85% gross margins, with Q1 2026 revenue of $26.5 million (29% YoY). The company is expanding its clinical indications — including FDA Breakthrough Device Designation for Large Vessel Occlusion stroke detection (January 2026), FDA clearance for AI-powered delirium monitoring (December 2025), and FDA 510(k) clearance of the Clarity algorithm for neonates (November 2025) — while pursuing active ITC patent litigation against incumbent EEG vendor Natus.

Name

Ceribell

Legal name

Ceribell, Inc.

Website

https://ceribell.com

Company type

Public

Founded year

2014

Operating status

Ipo

Headcount range

251–500 employees

Short description

Ceribell (NASDAQ: CBLL) is a publicly traded medical technology company that sells a portable, cloud-connected EEG platform with the FDA-cleared Clarity AI algorithm for rapid bedside seizure and brain monitoring in U.S. hospitals, ICUs, emergency departments, and neonatal/pediatric care settings.

Ownership category

akta.pro rank

Product category

Neurology Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industries

Neurology Telemedicine Platforms (HLALAGAC), Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ), Epilepsy & Seizure Disorders (HLAKAIAB), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)

Keywords

• Point-of-care EEG
• AI seizure detection
• Brain monitoring devices
• Neurology medical devices
• EEG headbands

Headquarters

HQ city

Mountain View

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure, Operations

Revenue model

1. Hardware Sales: Revenue from sale of the Ceribell EEG recorder and disposable headbands (single-use electrodes). The recorder is typically deployed with the customer, and headbands generate recurring consumable revenue per patient monitoring session.

Pricing tiers

Go-to-market motion1 record

Core offering

Ceribell develops and sells a point-of-care EEG brain monitoring platform that combines a portable handheld recorder, disposable single-use headbands, and the FDA-cleared Clarity AI algorithm to enable non-specialist clinical staff to perform bedside brain monitoring and seizure detection within minutes. The system is paired with a FedRAMP High-authorized cloud-based EEG Portal for remote neurologist review and is deployed across ICU, emergency department, neurology, pediatric ICU, and neonatal ICU settings in U.S. hospitals.

Product overview

Ceribell offers a platform-plus-modules architecture centered on a single unified point-of-care EEG hardware system. The core is the Ceribell Point-of-Care EEG System — a portable, wearable EEG hardware platform (recorder + disposable headband) that any trained provider can deploy at the bedside in minutes. Layered on this hardware are three software/service modules: the Clarity® AI Algorithm (cloud-based seizure-detection and seizure-burden AI that triggers bedside alerts), the Ceribell EEG Portal (a FedRAMP High-authorized cloud platform for remote review, reporting, and notifications), and the Brain Stethoscope® sonification feature. The Neonatal Headband is a specialized hardware accessory that pairs with the same core system and Clarity algorithm to extend coverage to preterm and newborn patients.

Differentiator

Problem solved

Functional benefit

Brands

• Clarity: Ceribell's proprietary AI algorithm that interprets EEG waveforms, detects seizures, and provides real-time bedside alerts for status epilepticus across all age groups (preterm neonates through adults).
• Ceribell System (Ceribell Point-of-Care EEG)
• Ceribell EEG Portal

Products and services

• Ceribell Point-of-Care EEG System A portable, wearable EEG hardware platform combining a disposable headband with a handheld recorder that enables any trained healthcare provider to initiate brain monitoring at the bedside in minutes without an EEG technician. Designed for ICU, ED, neurology, pediatric ICU, and neonatal ICU use; FDA 510(k)-cleared (K223504) for indicating suspected seizure activity.
• Clarity AI Algorithm Proprietary cloud-based machine-learning algorithm that continuously interprets the patient's EEG waveforms every 10 seconds to compute a 5-minute seizure burden estimate and trigger bedside alerts for suspected status epilepticus and continuous seizures. FDA-cleared for adults, pediatric patients (2025), and neonates (2025). Validated in 35+ publications with 95% sensitivity and 97% specificity at ≥90% seizure burden.
• Ceribell EEG Portal Intuitive, FedRAMP High-authorized cloud-based management platform for remote, real-time review of Ceribell EEG recordings with pre-annotated Clarity AI insights, custom notifications, smart EEG reports, and an embedded expert-annotated EEG Reference Library. Supports desktop and mobile review for neurologists, ICU, and ED teams.
• Ceribell Neonatal Headband (EEG Headcap) Disposable silicone-barrier EEG headcap designed for preterm and newborn infants (head circumference 26–46.5 cm) with protective skin barrier, easy fontanelle access for head ultrasounds, and stretchable fabric. Pairs with the Ceribell Point-of-Care EEG System and Clarity algorithm (FDA-cleared for neonates).
• Brain Stethoscope Sonification feature used with the Ceribell EEG system that converts EEG patterns into audible sounds, evaluated in the DECIDE trial where ED physicians identified seizures with 100% sensitivity and 92% specificity using Brain Stethoscope combined with Ceribell EEG.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability1 record

Feature6 records

Recent moves7 records

Expansion highlights7 records

Emerging players

• iCE Neurosciences: Emerging continuous EEG monitoring platform focused on critical care. Direct overlap with Ceribell's ICU/CCU use case but with a smaller commercial footprint; relevant as a niche next-generation competitor.
• Cumulus Neuroscience: Emerging EEG and digital biomarker platform with cloud-based analytics, primarily used in clinical trials and CNS drug development. Partially comparable to Ceribell's EEG Portal/Clarity platform for cloud-based EEG analysis, with a different end-customer focus (pharma/biotech).

Direct peers

• Natus Medical: The dominant legacy neurodiagnostic equipment vendor, with conventional EEG systems, long-term monitoring, and ICU EEG offerings. Directly comparable to Ceribell across Ceribell's core U.S. EEG customer base, and is the explicit defendant in Ceribell's ongoing ITC patent litigation.
• Wave Neuroscience: EEG-based diagnostic and therapeutic device company with focus on neurological assessment and brain injury. Operates in the same EEG/neuromonitoring category as Ceribell and is a relevant emerging competitor in the U.S. neurodiagnostic market.
• Cadwell Industries: Privately held neurodiagnostic and sleep-diagnostic equipment manufacturer selling EEG, EMG, and IOM systems into U.S. hospitals. Directly comparable as a long-standing specialty EEG competitor to Ceribell's point-of-care platform.
• Compumedics: Australia-based neurodiagnostic and sleep-diagnostic equipment maker (Neuvo, E-Series, Profusion) used in hospitals and research settings. Comparable as a specialty EEG and sleep-monitoring hardware/software vendor targeting similar hospital customers.
• Lifelines Neuro (Stratus EEG): EEG hardware and cloud review platform (Stratus EEG, Trackit) used in ICU, EMU, and ambulatory settings. Closely comparable to Ceribell's hardware-plus-portal model, particularly for ambulatory and EMU EEG, and competes for the same neurology and ICU budgets.

Broad incumbents

• Masimo: Large patient-monitoring incumbent with hospital-wide bedside monitoring, including EEG-adjacent brain-monitoring products (e.g., SedLine). Sells into the same ICU customer base as Ceribell and represents a broader, more diversified incumbent in the hospital monitoring category.
• Philips: Global medtech incumbent with a large hospital patient-monitoring portfolio and a dedicated neurodiagnostic EEG line. Competes for the same hospital EEG budgets as part of a much broader monitoring, imaging, and clinical informatics portfolio.
• Medtronic: Large neurology-focused medtech incumbent with brain and spinal therapies. While not a direct EEG hardware peer, it occupies the broader neurology hospital ecosystem in which Ceribell sells and could plausibly enter bedside brain monitoring via M&A or internal development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/ceribelleeg?lang=en
• YouTubeyoutube.com/@ceribellEEG
• Facebookfacebook.com/61554263476690
• LinkedInlinkedin.com/company/ceribell
• Instagraminstagram.com/ceribellpoceeg

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ceribell